We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00056147
First Posted: March 7, 2003
Last Update Posted: January 29, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Cystic Fibrosis Foundation Therapeutics
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
March 6, 2003
March 7, 2003
January 29, 2015
April 2003
February 2004   (Final data collection date for primary outcome measure)
  • lung function
  • respiratory symptoms
  • sputum weight
  • pulmonary exacerbations
  • measures of lung characteristics
Not Provided
Complete list of historical versions of study NCT00056147 on ClinicalTrials.gov Archive Site
safety measures
Not Provided
Not Provided
Not Provided
 
Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease
Multi-Center, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of INS37217 Inhalation Solution in Subjects With Mild to Moderate Cystic Fibrosis Lung Disease
The purpose of this study is to assess the safety and effectiveness of multiple dosages of INS37217 compared to placebo over 28 days in subjects with mild to moderate cystic fibrosis (CF) lung disease. Study drug will be administered through a nebulizer (a device that delivers medication as a mist by breathing it in).

The purpose of this study is to:

  • assess the safety and efficacy of multiple dose levels of INS37217 compared to placebo over 28 days in subjects with mild to moderate CF lung disease;
  • explore evidence of activity of INS37217 and placebo administered via PARI LC STAR nebulizer;
  • identify dose(s) that will be studied in subsequent trials.
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Cystic Fibrosis
Drug: denufosol tetrasodium (INS37217)
Not Provided
Deterding RR, Lavange LM, Engels JM, Mathews DW, Coquillette SJ, Brody AS, Millard SP, Ramsey BW; Cystic Fibrosis Therapeutics Development Network and the Inspire 08-103 Working Group. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am J Respir Crit Care Med. 2007 Aug 15;176(4):362-9. Epub 2007 Apr 19.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
90
February 2004
February 2004   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • confirmed diagnosis of CF
  • FEV1 greater than or equal to 75% of predicted normal for age, gender, and height
  • oxyhemoglobin saturation greater than or equal to 90%
  • clinically stable

Exclusion Criteria:

  • abnormal renal or liver function
  • clinically significant findings atypical for moderate cystic fibrosis
Sexes Eligible for Study: All
8 Years to 50 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT00056147
08-103
Not Provided
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Cystic Fibrosis Foundation Therapeutics
Study Director: Amy Schaberg, BSN
Merck Sharp & Dohme Corp.
January 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP